Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$20.03 USD
+0.66 (3.41%)
Updated Jul 22, 2024 02:56 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PCRX 20.03 +0.66(3.41%)
Will PCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
Other News for PCRX
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)
Insider Sale: Chief Administrative Officer Kristen Williams Sells Shares of Pacira BioSciences ...
Insider Sale at Pacira BioSciences Inc (PCRX): Senior Vice President, Finance Lauren Riker ...